June 27, 2024
3 min watch
Save
VIDEO: Outlook Therapeutics enrolling patients in trial of ONS-5010
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Russ Trenary, president and CEO of Outlook Therapeutics, discusses the development of ONS-5010.
ONS-5010/Lytenava (bevacizumab-vikg), a formulation of bevacizumab for the treatment of wet age-related macular degeneration, is planned to launch in Europe in the first quarter of 2025. Meanwhile, researchers in the U.S. are enrolling patients in an FDA trial to evaluate ONS-5010.
“The primary endpoint for this study is at 8 weeks, and we’ll be looking at best corrected visual acuity and a noninferiority margin of 3.5 letters,” Trenary said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Trenary reports being the president and CEO of Outlook Therapeutics.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.